Zydus Wellness
Zydus Wellness Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #22 of 31 in Food Products
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
The company expects continued double-digit growth, maintaining strong momentum in both domestic and international markets. Comfort Click business is EPS accretive since Q4 FY26 and expects margin and profit before tax to improve if current momentum continues.
From Zydus Wellness's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company expects continued double-digit growth, maintaining strong momentum in both domestic and international markets.
- Protein portfolio growth is expected to diversify, with bars currently leading but beverages and snacks also showing substantial potential over the next three years.
- Innovations like new protein bars (millet-based wafer bars), traditional products (Roots), Korean chips, RTDs, and expanded Max Protein cookies aim to drive faster acceptance and growth.
- Comfort Click is EPS accretive and expected to increase margins and profit before tax, with ongoing international expansion including the U.S. and Middle East.
- Complan is growing well despite category degrowth, driven by segmented nutrition offerings and new formats like RTD beverages.
2 more points from Zydus Wellness's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zydus Wellness said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- There is a focus on expanding product portfolios (e.g., new protein bars, RTDs, Korean chips) and distribution reach, which may imply ongoing strategic investments in innovation and market expansion.
- The company is investing in brand building, particularly in Comfort Click, including digital-first consumer engagement and expanding presence in new markets like the U.S. and Middle East.
- They are strengthening infrastructure for quick commerce and expanding offline distribution selectively, which might involve capital investment.
2 more points from Zydus Wellness's call on capex
Create a free account to keep reading this call
Top-ranked in Food Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zydus Wellness said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Zydus Wellness said on order book & pipeline — free account, 30 seconds.
Zydus Wellness — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.5K Cr, net profit ₹162 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zydus Wellness's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Food Products this season
- Wardwizard Foods (Q1 FY27)
Revenue for Q1 FY27 (June 2026 quarter) is ₹17.03 Cr, up from ₹13.20 Cr in Q1 FY26, reflecting a strong year-on-year growth. Key investor presentation takeaways
- Chemkart India (Q1 FY27)
Revenue from operations for Apr–Jun FY27 reported at INR 99.60 crore (INR 9,960.22 lakhs). Key investor presentation takeaways from Chemkart India Ltd's Q1 FY27
- Sheetal Cool (Q1 FY27)
Revenue from Operations for FY26: ₹366.0 Crores, up 13.9% YoY from ₹321.3 Crores in FY25 (Page 29, 5). Key investor presentation takeaways from Sheetal Cool Pro
- Mukka Proteins (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹489.7 crore . Key concall takeaways from Mukka Proteins Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Food Products
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zydus Wellness and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zydus Wellness Q1 FY27 results?
The company expects continued double-digit growth, maintaining strong momentum in both domestic and international markets. Comfort Click business is EPS accretive since Q4 FY26 and expects margin and profit before tax to improve if current momentum continues.
What is Zydus Wellness share price analysis?
Zydus Wellness currently shows a below-average growth signal. The stock trades at a P/E of 70.5 with a market cap of ₹15,615 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Wellness planning capital expenditure?
- There is a focus on expanding product portfolios (e.g., new protein bars, RTDs, Korean chips) and distribution reach, which may imply ongoing strategic investments in innovation and market expansion. - The company is investing in brand building, particularly in Comfort Click, including digital-first consumer engagement and expanding presence in new markets like the U.S.
Keep Zydus Wellness on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.